

Ichiro Ieiri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4092078/publications.pdf>

Version: 2024-02-01

103
papers

5,778
citations

81743

39
h-index

74018

75
g-index

106
all docs

106
docs citations

106
times ranked

4691
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 554-565. | 2.3 | 466 |
| 2 | Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 101-110. | 0.7 | 326 |
| 3 | Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 209-219. | 2.3 | 275 |
| 4 | FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA. <i>Drug Metabolism and Disposition</i> , 2005, 33, 94-101. | 1.7 | 269 |
| 5 | Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 175-184. | 5.7 | 242 |
| 6 | Functional Analysis of SNPs Variants of BCRP/ABCG2. <i>Pharmaceutical Research</i> , 2004, 21, 1895-1903. | 1.7 | 231 |
| 7 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 703-729. | 1.5 | 194 |
| 8 | Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese Population. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 243-247. | 1.0 | 188 |
| 9 | Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. <i>Journal of Human Genetics</i> , 2007, 52, 117-122. | 1.1 | 182 |
| 10 | Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 427-439. | 2.3 | 173 |
| 11 | The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics. <i>Epilepsia</i> , 1998, 39, 1317-1323. | 2.6 | 171 |
| 12 | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. <i>Transplantation</i> , 2002, 74, 571-572. | 0.5 | 164 |
| 13 | Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and) Tj ETQq1,1 0.784314 rgBT 0.6 150 | 0.6 | 150 |
| 14 | Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 749-757. | 5.7 | 140 |
| 15 | The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2004, 43, 553-576. | 1.6 | 138 |
| 16 | Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 85-89. | 5.7 | 135 |
| 17 | Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2). <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 85-105. | 1.1 | 134 |
| 18 | Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 647-653. | 2.3 | 123 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Polymorphism in human organic cation transporters and metformin action. <i>Pharmacogenomics</i> , 2008, 9, 415-422. | 0.6 | 119 |
| 20 | Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an <i>in vivo</i> inhibitor of BCRP. <i>British Journal of Pharmacology</i> , 2012, 166, 1793-1803. | 2.7 | 118 |
| 21 | Genetic Polymorphism of the CYP2C Subfamily and Excessive Serum Phenytoin Concentration With Central Nervous System Intoxication. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 230-232. | 1.0 | 118 |
| 22 | Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (<i>SLCO2B1</i>), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1078-1089. | 1.0 | 91 |
| 23 | An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 809-822. | 1.5 | 78 |
| 24 | Genetic polymorphisms and functional characterization of the 5' flanking region of the human CYP2C9 gene: In vitro and in vivo studies. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 175-182. | 2.3 | 76 |
| 25 | Catalytic Activity of Three Variants (Ile, Leu, and Thr) at Amino Acid Residue 359 in Human CYP2C9 Gene and Simultaneous Detection Using Single-Strand Conformation Polymorphism Analysis. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 237-244. | 1.0 | 76 |
| 26 | Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1427-33. | 2.8 | 73 |
| 27 | Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. <i>Journal of Human Genetics</i> , 2006, 51, 822-826. | 1.1 | 64 |
| 28 | Drug-drug interactions that interfere with statin metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1435-1447. | 1.5 | 63 |
| 29 | Apple juice greatly reduces systemic exposure to atenolol. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 172-179. | 1.1 | 60 |
| 30 | Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 651-674. | 1.5 | 52 |
| 31 | Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 78-86. | 1.1 | 51 |
| 32 | Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. <i>Human Molecular Genetics</i> , 2004, 13, 2959-2969. | 1.4 | 49 |
| 33 | Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1165-1169. | 1.1 | 49 |
| 34 | Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 495-505. | 0.7 | 44 |
| 35 | Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. <i>Hepatology Research</i> , 2004, 30, 91-95. | 1.8 | 43 |
| 36 | 5' Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. <i>Blood</i> , 2004, 103, 3055-3057. | 0.6 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2688-2694. | 1.6 | 43 |
| 38 | Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 115-119. | 1.1 | 41 |
| 39 | Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1622-1632. | 1.7 | 41 |
| 40 | Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. <i>Journal of Neurochemistry</i> , 2019, 148, 373-385. | 2.1 | 40 |
| 41 | Severe Toxicities After Irinotecan-Based Chemotherapy in a Patient With Lung Cancer: A Homozygote for the SLCO1B1*15 Allele. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 666-668. | 1.0 | 36 |
| 42 | Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. <i>Journal of Human Genetics</i> , 2008, 53, 899-904. | 1.1 | 36 |
| 43 | The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 352-357. | 1.1 | 31 |
| 44 | Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Clinical Pharmacokinetics</i> , 2019, 58, 403-420. | 1.6 | 31 |
| 45 | Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 851-859. | 0.7 | 29 |
| 46 | Epigenetic Regulation of Genes Encoding Drug-Metabolizing Enzymes and Transporters; DNA Methylation and Other Mechanisms. <i>Current Drug Metabolism</i> , 2008, 9, 34-38. | 0.7 | 29 |
| 47 | Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2015, 3, 68-73. | 0.2 | 27 |
| 48 | Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines. <i>Scientific Reports</i> , 2016, 6, 32299. | 1.6 | 24 |
| 49 | Epigenetic regulation of drug transporter expression in human tissues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 19-30. | 1.5 | 23 |
| 50 | Interindividual Differences in Placental Expression of the SLC22A2 (OCT2) Gene: Relationship to Epigenetic variations in the 5'-Upstream Regulatory Region. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3875-3883. | 1.6 | 21 |
| 51 | The relationship between fine particulate matter (PM2.5) and schizophrenia severity. <i>International Archives of Occupational and Environmental Health</i> , 2018, 91, 613-622. | 1.1 | 21 |
| 52 | Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on <i>SLCO1B1</i> and <i>ABCC2</i> Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1309-1317. | 1.0 | 20 |
| 53 | Efficacy of DPP4 inhibitors, GLP1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 393-402. | 1.1 | 19 |
| 54 | Association between DNA Methylation in the miR-328 5'-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta. <i>PLoS ONE</i> , 2013, 8, e72906. | 1.1 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. <i>Pharmacogenomics</i> , 2013, 14, 1745-1764. | 0.6 | 17 |
| 56 | Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the <i>ABCG2</i> gene. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1236-1237. | 1.1 | 17 |
| 57 | Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1013-1023. | 1.1 | 17 |
| 58 | Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human <i>ABCC3</i> Gene. <i>Drug Metabolism and Disposition</i> , 2018, 46, 628-635. | 1.7 | 17 |
| 59 | Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. <i>Scientific Reports</i> , 2021, 11, 15057. | 1.6 | 17 |
| 60 | Systematic Screening of Human <i>ABCC3</i> Polymorphisms and Their Effects on <i>MRP3</i> Expression and Function. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 374-386. | 1.1 | 16 |
| 61 | Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-mediations based on electronic medical records. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 824-835. | 1.1 | 15 |
| 62 | Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 344-354. | 0.7 | 15 |
| 63 | Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 803-813. | 1.1 | 14 |
| 64 | Nucleosome Positioning and Gene Regulation of the <i>SGLT2</i> Gene in the Renal Proximal Tubular Epithelial Cells. <i>Molecular Pharmacology</i> , 2018, 94, 953-962. | 1.0 | 13 |
| 65 | Detection of overdose and underdose prescriptions—An unsupervised machine learning approach. <i>PLoS ONE</i> , 2021, 16, e0260315. | 1.1 | 12 |
| 66 | Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 351-361. | 0.8 | 9 |
| 67 | Regulation of Organic Anion Transporting Polypeptide 2B1 Expression by MicroRNA in the Human Liver. <i>Molecular Pharmaceutics</i> , 2020, 17, 2821-2830. | 2.3 | 9 |
| 68 | Identification and Functional Characterization of Novel Nonsynonymous Variants in the Human Multidrug and Toxin Extrusion 2-K. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1432-1437. | 1.7 | 8 |
| 69 | Relationship between DNA Methylation in the 5 ^α CpG Island of the <i>SLC47A1</i> (Multidrug and Toxin) Tj ETQq1 1 0.784314 rgBT <i>Molecular Pharmacology</i> , 2018, 93, 1-7. | 1.0 | 8 |
| 70 | Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406. <i>Clinical Pharmacokinetics</i> , 2022, 61, 955-972. | 1.6 | 7 |
| 71 | The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. <i>Life Sciences</i> , 2022, 288, 120150. | 2.0 | 6 |
| 72 | ANALYSIS OF THE FACTORS INFLUENCING ANTI-EPILEPTIC DRUG CONCENTRATIONS-VALPROIC ACID. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1990, 15, 351-363. | 0.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Hydroxylation of Phenytoin (PHT) and the Cytochrome P450(CYP) 2C Subfamily. <i>Epilepsia</i> , 1998, 39, 82-83. | 2.6 | 4 |
| 74 | Multiple gene polymorphisms and warfarin sensitivity. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 881-883. | 0.8 | 4 |
| 75 | Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 615-621. | 1.2 | 4 |
| 76 | Population Pharmacodynamic Analysis of Uric Acidâ€“Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 304-313. | 1.0 | 4 |
| 77 | Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. <i>Toxicology Letters</i> , 2021, 341, 43-50. | 0.4 | 4 |
| 78 | Development and Validation of A Liquid Chromatographyâ€“Tandem Mass Spectrometry Method to Simultaneously Measure Tacrolimus and Everolimus Concentrations in Kidney Allograft Biopsies After Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 275-281. | 1.0 | 3 |
| 79 | Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 829-834. | 1.0 | 3 |
| 80 | Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. <i>Drugs in R and D</i> , 2021, 21, 419-429. | 1.1 | 3 |
| 81 | Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 404-413. | 1.0 | 3 |
| 82 | Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1282-1286. | 1.2 | 2 |
| 83 | Effect of Genetic Polymorphisms of Human SLC22A3 in the 5â€™-flanking Region on OCT3 Expression and Sebum Levels in Human Skin. <i>Journal of Dermatological Science</i> , 2021, 101, 4-13. | 1.0 | 2 |
| 84 | Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 41, 100403. | 1.1 | 2 |
| 85 | Development and Full Validation of a Bioanalytical Method for Quantifying Letermovir in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry. <i>Chemical and Pharmaceutical Bulletin</i> , 2021, 69, 646-651. | 0.6 | 2 |
| 86 | Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2021, 7, 39. | 0.4 | 2 |
| 87 | Simplified daptomycin dosing regimen for adult patients with methicillin-resistant <i>Staphylococcus aureus</i> infections based on population pharmacokinetic analysis. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 44, 100444. | 1.1 | 2 |
| 88 | A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TASâ€“114. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 604-615. | 1.3 | 2 |
| 89 | ANALYSIS OF THE FACTORS INFLUENCING ANTI-EPILEPTIC DRUG CONCENTRATIONS-CARBAMAZEPINE. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1990, 15, 337-349. | 0.7 | 1 |
| 90 | Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 264-269. | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer. <i>Annals of Pharmacotherapy</i> , 2021, 55, 738-744. | 0.9 | 1 |
| 92 | Predictive performance of Bayesian method in a simulation work: One-compartment open linear model containing an oral route.. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 1988, 19, 597-606. | 0.1 | 1 |
| 93 | Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkinâ€™s Lymphoma Receiving ESHAPâ€±R Therapy. <i>Anticancer Research</i> , 2022, 42, 2053-2060. | 0.5 | 1 |
| 94 | Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide. <i>Genes</i> , 2021, 12, 2026. | 1.0 | 1 |
| 95 | Evaluation of Medication Instruction Sheets for Patients Undergoing R-CHOP Therapy in Non-Hodgkinâ€™s Lymphoma. <i>In Vivo</i> , 2022, 36, 1461-1467. | 0.6 | 1 |
| 96 | Studies on Pharmacoepidemiology of Antiepileptic Adverse Reactions (2). <i>Psychiatry and Clinical Neurosciences</i> , 1991, 45, 464-467. | 1.0 | 0 |
| 97 | The effect of 5â€“(pâ€“hydroxyphenyl)â€“5â€“phenylhydantoin (pâ€“HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic side effects: <i>In vivo</i> and <i>in vitro</i> studies. <i>Psychiatry and Clinical Neurosciences</i> , 1995, 49, S247-51. | 1.0 | 0 |
| 98 | Simultaneous determination of carbamate pesticides in human serum and urine by automatic reversed-phase HPLC combined with on-line column enrichment. <i>Bunseki Kagaku</i> , 2004, 53, 705-713. | 0.1 | 0 |
| 99 | Contribution of Angiotensin Converting Enzyme Gene Polymorphism to the Action of Angiotensin II Receptor Antagonist (CS-866).. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2002, 33, 37-46. | 0.1 | 0 |
| 100 | ï¼¼ï¼¼ŽæŠ—è...«ç~è--ã•PGx. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2008, 39, 233-237. | 0.1 | 0 |
| 101 | The Effect of Phenytoin Withdrawal on Valproic Acid Free Fraction: A Case Report.. <i>Japanese Journal of Hospital Pharmacy</i> , 1991, 17, 52-58. | 0.0 | 0 |
| 102 | Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Childâ€™Pugh and MELD scores. <i>British Journal of Clinical Pharmacology</i> , 2022, , . | 1.1 | 0 |
| 103 | Experimental Survey of Anticancer Drug Contamination from Disposal Containers to Prevent Occupational Exposure. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2021, 47, 200-207. | 0.0 | 0 |